Roivant Sciences

ROIV · NASDAQ

$34.92+$0.22 (+0.63%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $34.70

ROIV analyst rating

BuyConsensus of 10 analysts over the last 12 months. 90% rate it a buy.

Strong buy0
Buy9
Hold1
Underperform0
Sell0

12-month price target · 15 analysts

Average $49.62 (+42.1% upside)

Low: $36.14
Now: $34.92
High: $71.40

Upgrades and downgrades

The latest rating actions, newest first

ROIV analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wolfe Research	Oct 12, 2026	Downgrade	Outperform → Peer Perform	—	47%
Stifel	Sep 17, 2026	Initiates	Buy	$51.00	59%
TD Cowen	Sep 9, 2026	Maintains	Buy	$50.00 → $55.00	49%
Guggenheim	Sep 9, 2026	Maintains	Buy	$42.00 → $46.00	49%
HC Wainwright & Co.	Sep 8, 2026	Maintains	Buy	$41.00 → $47.00	50%
Jefferies	Sep 8, 2026	Maintains	Buy	$42.00 → $52.00	25%
HC Wainwright & Co.	Aug 28, 2026	Maintains	Buy	$41.00	50%
Citigroup	Aug 10, 2026	Maintains	Buy	$42.00 → $46.00	36%
Guggenheim	Aug 7, 2026	Maintains	Buy	$36.00 → $42.00	49%
HC Wainwright & Co.	Aug 7, 2026	Maintains	Buy	$34.00 → $41.00	50%

The case for and against

Updated Oct 18, 2026

Bull case

Roivant Sciences is supported by a strengthening fundamental story built on multiple late-stage and commercial catalysts, led by VTAMA already in the market and brepocitinib, now branded Lisraya, becoming the first targeted therapy approved for adult dermatomyositis. Its pipeline also shows unusually strong clinical execution, with mosliciguat in PH-ILD delivering a 56.3% placebo-adjusted PVR reduction at Week 16, +35.2 meters in 6MWD, and supportive NT-proBNP improvement, while Phase III PHrontier has already been initiated. These results expand the company’s commercial optionality across high-unmet-need indications, with approximately $3B peak sales potential estimated for mosliciguat and durable differentiation from steroid-sparing benefits, once-daily dosing, and strong tolerability.

Bear case

Roivant Sciences is fundamentally challenged by a pipeline that has already shown clinical and execution risk, including failures of IMVT assets in non-infectious uveitis and cutaneous sarcoidosis, failure of mosliciguat in PH-ILD, and unanticipated safety issues across batoclimab, IMVT-1402, brepocitinib, and other programs. The investment case is also weakened by litigation setbacks, unaudited financial statements, and the fact that key products remain unapproved while facing regulatory, technical, and commercial risks in competitive markets dominated by larger, more experienced players. Although VTAMA is commercial-stage and valuation work points to a 2036 discounted risk-adjusted revenue estimate of $2.5B, that upside is heavily dependent on uncertain probabilities of success across multiple assets, leaving the stock’s fundamentals fragile.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.